Cytokinetics, Incorporated
General ticker "CYTK" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $8.1B (TTM average)
Cytokinetics, Incorporated follows the US Stock Market performance with the rate: 43.5%.
Estimated limits based on current volatility of 2.0%: low 61.82$, high 64.31$
Factors to consider:
- Total employees count: 673 (+35.1%) as of 2025
- China accounted for 17.9% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Lack of market acceptance, Clinical trial failure, Regulatory and compliance, Manufacturing issues, Insufficient capital
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [37.15$, 93.22$]
- 2026-12-31 to 2027-12-31 estimated range: [26.63$, 70.35$]
Financial Metrics affecting the CYTK estimates:
- Negative: with PPE of -9.7 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: Inventory ratio change, % of 72.12 > 4.02
- Negative: Shareholder equity ratio, % of -46.30 <= 7.04
- Negative: negative Industry operating income (median)
- Negative: negative Industry operating cash flow (median)
- Negative: Investing cash flow per share per price, % of 0.22 <= 2.08
- Negative: 0.75 < Interest expense per share per price, % of 1.37
Short-term CYTK quotes
Long-term CYTK plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $7.53MM | $18.47MM | $88.04MM |
| Operating Expenses | $503.74MM | $554.72MM | $700.30MM |
| Operating Income | $-496.20MM | $-536.25MM | $-612.26MM |
| Non-Operating Income | $-30.04MM | $-53.28MM | $-172.70MM |
| Interest Expense | $57.67MM | $86.51MM | $103.87MM |
| R&D Expense | $330.12MM | $339.41MM | $405.90MM |
| Income(Loss) | $-526.24MM | $-589.53MM | $-784.96MM |
| Net Income(Loss)* | $-526.24MM | $-589.53MM | $-784.96MM |
| Stockholders Equity | $-386.32MM | $-135.37MM | $-659.62MM |
| Assets | $824.32MM | $1,401.67MM | $1,424.54MM |
| Operating Cash Flow | $-414.33MM | $-395.89MM | $-510.01MM |
| Capital expenditure | $1.42MM | $3.91MM | $24.81MM |
| Investing Cash Flow | $239.25MM | $-553.10MM | $16.67MM |
| Financing Cash Flow | $221.32MM | $930.61MM | $524.46MM |
| Earnings Per Share** | $-5.45 | $-5.26 | $-6.54 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.